
Sanofi is doubling down on autoimmune R&D with another bispecific antibody partnership—this time with Earendil Labs.
The deal could reach $2.5B, underscoring how big pharma continues to rely on external platforms to strengthen early discovery in complex disease areas.
Source: Fierce Biotech
#Biotech #Autoimmune #DrugDevelopment #BigPharma

English













